SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

01 Nov 2023 Evaluate
The revenue zoomed 23.38% to Rs. 1713.15 millions for the quarter ended September 2023 as compared to Rs. 1388.49 millions during the corresponding quarter last year.A good growth in profit of 33.18% reported to Rs. 338.91  millions over Rs. 254.47 millions of corresponding previous quarter.Operating profit for the quarter ended September 2023 rose to 529.22 millions as compared to 408.66 millions of corresponding quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 1713.15 1388.49 23.38 2803.07 2861.29 -2.03 5983.40 6363.57 -5.97
Other Income 106.14 142.31 -25.42 171.41 328.65 -47.84 507.66 326.28 55.59
PBIDT 529.22 408.66 29.50 705.00 786.47 -10.36 1409.21 1418.26 -0.64
Interest 11.78 18.39 -35.94 24.87 38.81 -35.92 100.57 43.24 132.59
PBDT 517.44 390.27 32.59 680.13 747.66 -9.03 1308.64 1402.47 -6.69
Depreciation 56.78 37.35 52.02 110.42 74.09 49.03 151.73 138.47 9.58
PBT 460.66 352.92 30.53 569.71 673.57 -15.42 1156.91 1264.00 -8.47
TAX 121.75 98.45 23.67 155.84 172.66 -9.74 302.14 337.36 -10.44
Deferred Tax 1.29 7.55 -82.91 8.29 -4.70 -276.38 -42.10 7.68 -648.18
PAT 338.91 254.47 33.18 413.87 500.91 -17.38 854.77 926.64 -7.76
Equity 104.40 103.89 0.49 104.40 103.89 0.49 104.15 103.68 0.45
PBIDTM(%) 30.89 29.43 4.96 25.15 27.49 -8.50 23.55 22.29 5.68

Bliss GVS Pharma Share Price

258.35 -0.95 (-0.37%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×